Skip to main
GUTS

GUTS Stock Forecast & Price Target

GUTS Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 75%
Buy 0%
Hold 25%
Sell 0%
Strong Sell 0%

Bulls say

Fractyl Health is a clinical stage company with a promising lead product candidate, Revita, that has shown potential to address the root causes of obesity and type 2 diabetes. The recent updates on key trial results and design, including a significant correlation between ablation length and weight maintenance, provide further support for the efficacy and potential of Revita in the market. Taking into consideration the company's strong financials and potential for future growth, it is likely that Fractyl's stock will continue to perform well in the coming years.

Bears say

Fractyl Health is a clinical stage metabolic therapeutics company with promising candidates for treating obesity and T2D, but it faces several challenges, including a lack of significant statistical significance and concerns about weight regain kinetics. The recent announcement of positive results from its REVEAL-1 and REMAIN-1 studies strengthen the potential efficacy and durability of its lead product, Revita. However, the company's financials show no current sources of revenue, and the outcome of its pivotal trial in 2026 will be a crucial factor for its future success.

GUTS has been analyzed by 4 analysts, with a consensus rating of Buy. 75% of analysts recommend a Strong Buy, 0% recommend Buy, 25% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Fractyl Health Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Fractyl Health Inc (GUTS) Forecast

Analysts have given GUTS a Buy based on their latest research and market trends.

According to 4 analysts, GUTS has a Buy consensus rating as of Apr 29, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $5.40, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $5.40, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Fractyl Health Inc (GUTS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.